Diabetes-related therapy candidate stars in $700 million-plus Merck & Co deal


Diabetes-related therapy candidate stars in $700 million-plus Merck & Co deal

East Coast, USA, protease inhibitor specialist KalVista Pharmaceuticals (Nasdaq: KALV) has signed a deal with Merck & Co (NYSE: MRK), sending shares in the thinly-traded startup through the roof.

Under the terms of the deal, Merck will pay $37 million upfront, and there is a potential for some $700 million or more in milestone payments and royalties, if all goes well.

Merck will acquire a near-10% stake in the firm, which saw its share price double…

Try before you buy

7 day trial access

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

or £77 per month

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

If you are already a registered user pleaselogin.
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK

DealsKalVista PharmaceuticalsKVD001LicensingMerck & CoOphthalmicsPharmaceuticalResearchUSA

Back to top